Novoloop Raises $21 Million Series B Funding Led by Taranis to Scale Circular Performance Materials
This latest funding round brings Novoloop's total capital raised to over $50 million and marks a continuation of the company's significant momentum—demonstrated by achieving continuous operations at its demonstration plant in India, strategic partnerships with world-leading polyurethane producers in China, and progress toward siting its first commercial facility. With continued backing from existing investor Valo Ventures, the round also welcomed new investment from SHOP Limited, the Family Office of the Bata Shoe Company.
'We are thrilled to partner with Taranis, whose deep commitment in plastic circularity and industrial decarbonization aligns with our ambition to scale Lifecycling™ globally,' said Miranda Wang, CEO and Co-Founder of Novoloop. 'This round positions us to meet growing demand from a wider supply chain seeking circular and cost-competitive polyurethanes through the industrial scale-up of our first-of-a-kind technology.'
Taranis brings deep operational and technical expertise in scaling pioneering industrial technologies and solutions that enable the circular transformation of hard-to-abate sectors. The investment affirms Novoloop's role at the forefront of circular materials innovation and recognizes its unique ability to deliver scalable impact by displacing fossil-based inputs in everyday products.
'As the world looks to decarbonize materials and eliminate waste, Novoloop offers a breakthrough solution for upcycling polyethylene—one of the hardest plastics to recycle,' said David Sorin, Managing Director of Taranis. 'Their technology fits within our mission to decarbonize heavy industries and scale circular infrastructure. We are proud to back the team in building a more circular, low-carbon plastics economy.'
About Novoloop
Novoloop is a circular innovation company transforming hard-to-recycle plastics with its proprietary Lifecycling™ technology. By chemically upcycling post-consumer polyethylene into high-performance, low-carbon polyols and polyurethanes, Novoloop enables sustainable materials for applications in footwear, apparel, automotive, and more. Founded in 2015 and based in California, the company has raised over $50 million and holds 50 granted and pending patents across 18 regions. Novoloop's Lifecycled™ TPU debuted in On's Cloudprime sneaker in 2022, and in 2025, the company was named one of TIME's World's Top Greentech Companies. Learn more at novoloop.com.
About Taranis
Taranis is an investment and impact project development entity of the Perenco Group. Its mission is to research, finance and operate innovative initiatives in the fields of sustainable energy, carbon management and nature-based solutions. Drawing on Perenco's industrial expertise, Taranis aims to reconcile economic performance and environmental responsibility, while generating a tangible social impact. For more information, visit taranis.eu.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
Sunflower Therapeutics Announces Exclusive Distribution Agreement with Alflow Scandinavia A/S
MEDFORD, Mass.--(BUSINESS WIRE)-- Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower's first commercial partnership in Europe, representing a key step in its international growth strategy. 'Expanding into Europe with a trusted and innovative partner like Alflow allows us to support a broader community of scientists and biomanufacturers,' said Dr. Kerry Love, CEO and co-founder of Sunflower Therapeutics. "Alflow's team brings a deep technical knowledge that aligns with our ongoing product commercialization goals and our objective of making protein manufacturing more intuitive, cost-effective, and efficient. We're excited to work with their team to bring our technology overseas to new markets.' Sunflower's innovative Daisy Petal™ is a breakthrough technology designed for high-efficiency protein production using an intuitive, single-use assembly. The system features a disposable stirred tank reactor with an integrated in-vessel cell retention device that enables continuous biomass feeding, fluid harvesting, and perfusion, which results in significantly higher space-time yields compared to traditional fed-batch fermentation. 'Partnering with Sunflower Therapeutics allows us to bring a truly novel bioreactor solution to the Nordic market,' said Jacob Rosenkrands, CEO of Alflow Scandinavia A/S. 'We are committed to offering our customers solutions that make a measurable difference. The Daisy Petal system stands out by combining simplicity, scalability, and performance – and we look forward to supporting our customers in bringing it into practice.' Sunflower's bioprocessing software suite, compliant with Good Manufacturing Practices (GMP) for use in regulated biomanufacturing, includes HelianthOS™, Nursery™, and Harvest™. These tools enable walkaway automation of fermentation processes, easy development of process recipes with no coding, and the secure storage of process data generated by the Daisy Petal™ System. Together, these three elements provide a cohesive ecosystem that enables efficient and intuitive operations throughout an entire campaign. To learn more about the Daisy Petal™, contact Alflow Scandinavia A/S at About Sunflower Therapeutics Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods and Contract Research Organization (CRO) services for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing. About Alflow Scandinavia A/S Alflow Scandinavia A/S is a Danish team of flow technology experts that delivers high-quality components, technical advice, and works in close collaboration with customers in the pharma, food, and single-use industries. With more than 25 years of experience, the company turns expertise into reliable solutions that create value, ensure safety – and deliver flow that makes a difference. Visit:
Business Wire
4 minutes ago
- Business Wire
CAMS Receives Best and Brightest Companies to Work For® in the Nation Award for Fourth Consecutive Year
HOUSTON--(BUSINESS WIRE)--Consolidated Asset Management Services (CAMS), a fully integrated service provider for owners of energy infrastructure assets, announced today that it has been recognized as one of The Best and Brightest Companies to Work For® in the Nation, by the National Association for Business Resources (NABR) for 2025. This is CAMS' fourth consecutive year winning this prestigious award. 'This award is a testament to our extraordinary employees and their consistent contribution of innovation and perseverance into our business practices and overall workplace environment," stated CAMS CEO and Founder Joseph W. Sutton Share The NABR Best and Brightest Program honors companies that consistently deliver the most innovative business acuteness and human resource practices. CAMS was assessed based on several key workplace measures including Compensation, Benefits, Employee Enrichment, Recruitment, Wellbeing Solutions, Work-Life Blend, Employee Achievement and Recognition, Community Initiatives and Corporate Responsibility, Communication and Shared Vision, as well as many others. "CAMS aims to foster a positive, growth-oriented work culture with excellent benefits and compensation, enabling our employees to deliver outstanding solutions and exceed client expectations," stated CAMS CEO and Founder Joseph W. Sutton. 'This award is a testament to our extraordinary employees and their consistent contribution of innovation and perseverance into our business practices and overall workplace environment.' The winners are determined by an independent research firm. The program's 10-to-1 ratio indicates that the companies selected have earned the honor due to their trailblazing efforts in employee engagement execution. All 2025 companies selected nationally as a Best and Brightest Company to Work For® will be featured in the online edition of Corp! Magazine and in the Wall Street Journal. 'These companies have excelled by prioritizing their workplace culture,' said President and CEO of NABR, Jennifer Kluger. 'By putting their employees first, this exceptional group of top-tier leaders has created a strong foundation that sets them apart as leaders in their industries and communities.' If you want to start a rewarding career at one of the nation's top workplaces, explore CAMS' job opportunities here. About CAMS CAMS is a privately held company providing Operations and Maintenance (O&M), Asset Management, Environmental, Social, and Governance (ESG), and Optimization services for energy and infrastructure assets. Our founding principle is to add value through superior management and operation of our clients' energy infrastructure assets. To this end, we empower our employees to pursue creative and sustainable business practices in the field and at our corporate office that contribute to operational excellence, financial performance, a safe workplace, and a better community and environment. We do not take this responsibility lightly: We treat the assets with which we are entrusted as our own. For additional information, visit
Business Wire
4 minutes ago
- Business Wire
Vida Health Appoints Leading Industry Executives to Accelerate Growth in Cardiometabolic Care
SAN FRANCISCO--(BUSINESS WIRE)-- Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity and related conditions, today announced the appointment of Jason Macaleer as Chief Strategy Officer and Mike Rolla as Chief Growth Officer. Seasoned healthcare leaders with a combined 40+ years of industry experience, Macaleer and Rolla will partner to help scale the company's impact amid growing demand for evidence-based obesity and cardiometabolic solutions. The announcement of Macaleer and Rolla's appointments coincides with the completion of Vida Health's recent capital raise led by existing investor General Atlantic, with participation from Ally Bridge, Canvas Prime, and existing shareholders, underscoring leading investors' support for the company's strong market traction. In the last year, Vida has experienced significant growth, expanding its customer base by 70% and increasing revenue by greater than 90% year-to-date, driven by the company's Clinical Obesity Management program. Combined with deepening partnerships with consultants, PBMs, and payers, this momentum underscores Vida's emergence as the preferred partner for cardiometabolic care, particularly amid rising concerns about GLP-1 affordability and sustainability. 'Jason and Mike's leadership and vision will be instrumental in our next phase of growth. Their complementary experience strengthens our ability to deliver sustainable solutions for obesity, diabetes, and related conditions,' said Joe Murad, CEO at Vida Health. 'With our recent capital raise, which fully funds Vida to profitability, we are even better positioned to deliver on our mission and expand our impact, backed by the continued confidence of our investors.' Macaleer joins Vida at a pivotal moment in the market, as employers and health plans navigate rising cardiometabolic risk and the evolving GLP-1 landscape. Macaleer brings deep expertise from strategic roles at Transcarent, Teladoc Health, and Livongo, where he scaled employer and health plan partnerships and advanced value-based care. He will support Vida's mission of delivering partners and their members measurable, meaningful health outcomes, personalized care, and cost savings. 'It is a privilege to join the Vida team as we work to help address the obesity epidemic,' said Jason Macaleer. 'I am energized by the opportunity to contribute to Vida's continued growth and drive impactful results for our partners and their members.' Rolla has a strong track record in commercializing innovative medical technologies and leading enterprise growth at companies like AliveCor, Teladoc/Livongo, and Becton Dickinson. His leadership in go-to-market strategy and complex enterprise sales will advance Vida's expansion of responsible GLP-1 prescribing and comprehensive obesity care. 'It is rewarding to be part of Vida at such an exciting time of accelerated growth,' said Mike Rolla. 'We are off to a strong start in 2025 and poised to continue our momentum with Jason and the rest of this impressive management team.' Together, both executives offer a powerful blend of strategic vision, commercial acumen, and operational expertise as they work to strengthen employer and payer partnerships, optimize Rx integration, and accelerate Vida's growth in the cardiometabolic market. To learn more about how Vida helps health plans and employers improve the health of their members and employees, visit About Vida Health Vida Health is a virtual, personalized obesity care provider that helps patients manage obesity and related conditions like diabetes, high blood pressure, anxiety, and depression with evidence-based treatment. Vida's team of obesity medicine-certified physicians, nurses, registered dietitians, expert coaches, and licensed therapists take a whole-person approach leading to clinically meaningful body weight loss in one year. Practicing responsible prescribing, Vida supports patients, employers, and health plans by prioritizing proven behavior change and lifestyle interventions before introducing medications, ensuring that only those who really need anti-obesity medications receive them — helping to control costs. For individuals with obesity, employers and health plans can save up to $550 in monthly prescription costs. Vida serves members in all 50 states and Washington D.C., offers services in both English and Spanish, and operates on a value-based pricing model, putting outcomes at the center of care. To learn more, visit
